Kiniksa Pharmaceuticals International (KNSA) Current Assets (2017 - 2026)

Kiniksa Pharmaceuticals International has reported Current Assets for 10 years, with the latest figure at $594.2 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 66.95% year-over-year to $594.2 million; the trailing twelve-month figure through Mar 2026 stood at $594.2 million (up 66.95% YoY), and the FY2025 full-year result was $527.2 million, up 58.88% from the prior year.
• Current Assets for Q1 2026 stood at $594.2 million, up from $527.2 million in the prior quarter.
• The five-year high for Current Assets was $594.2 million in Q1 2026, with the low at $179.9 million in Q2 2022.
• Historically, Current Assets has averaged $321.3 million across 5 years, with a median of $276.3 million in 2023.
• Annual changes were most pronounced in 2022 — Current Assets decreased 27.87% — and 2026, when it soared 66.95%.
• Kiniksa Pharmaceuticals International's Current Assets stood at $243.1 million in 2022, then grew by 13.67% to $276.3 million in 2023, then increased by 20.09% to $331.8 million in 2024, then soared by 58.88% to $527.2 million in 2025, then grew by 12.71% to $594.2 million in 2026.
• The last three Current Assets figures came in at $594.2 million (Q1 2026), $527.2 million (Q4 2025), and $475.5 million (Q3 2025), per Business Quant data.